Patent · US Active

Anti-TFPI antibody variants with differential binding across PH range for improved pharmacokinetics

US9556280B2 · kind B2 · utility

2Cited by
2References
6Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 14, 2014
Grant dateJan 31, 2017
Priority date
Expiry dateJul 9, 2034

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/94
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

Antibodies are disclosed that bind to and inhibit the anti-coagulant function of TFPI and have a lower affinity for TFPI at pH 6.0 than at pH 7.4. The lower affinity at pH 6 improves circulating half-life (T½) due to reduced target mediated clearance, a process by which an antibody/antigen complex is endocytosed and trafficked to the lysosome where both components are degraded. The lower affinity at pH 6.0 results in disruption of the complex prior to lysosome targeting and allows for re-circulation of the antibody. Specific modifications to antibody binding by histidine residue substitution are disclosed along with methods of use.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.